Company intelligence
Edwards Lifesciences
Global leader in the medical device industry with a patient-focused culture of innovation
About Edwards Lifesciences
Edwards Lifesciences (NYSE: EW), is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. We thrive on discovery and expanding the boundaries of medical technology, serving patients in 100+ countries, with the help of our employees in areas including Clinical Affairs, Quality Engineering, Research & Development, Regulatory Affairs, Sales & Marketing, corporate functions and more. Contact Us We want to hear from you and engage in meaningful discussions. However, please note that we are not equipped to provide customer, candidate, or technical support through this platform. If you require assistance from those teams, please find their contact information here: https://www.edwards.com/aboutus/contactus If you’re a patient in need of medical advice, please contact your healthcare provider directly. We reserve the right to remove any comments that are off-topic, repetitive, or include hate speech, profanity, or offensive language. Additionally, we will not engage in discussions about competitor products, off-label use of Edwards products, or unsubstantiated/misleading claims that could cause harm. All Terms and Conditions of LinkedIn apply. For the Edwards Lifesciences privacy policy, visit https://www.edwards.com/legal/privacypolicy.
Verified activity
Signals from Edwards Lifesciences
7 published signals
People
Edwards Lifesciences appointed Grace Song as Director of Global Marketing for Transcatheter Tricuspid Valve Replacement (TTVR).
Reported by Grace Song
Research & Knowledge
Edwards Lifesciences published a new study in the NEJM titled TRIC-I-HF reporting hard endpoint benefits for transcatheter tricuspid repair plus medical therapy versus medical therapy alone in severe TR patients at increased risk for future heart failure events.
Reported by Anna Kliefoth
Research & Knowledge
Edwards Lifesciences published a new study in the NEJM titled TRIC-I-HF reporting hard endpoint benefits for transcatheter tricuspid repair plus medical therapy versus medical therapy alone in severe TR patients at increased risk for future heart failure events.
Reported by Matt Booth
Presence & Recognition
Edwards Lifesciences announced that it is the first in-country hospital in the United States to receive a national grant for children's health.
Reported by Aaron Sanders
People
Edwards Lifesciences is hiring an Architect, IT Solutions, Copilot & Agentic AI Platforms to help shape how we scale Agentic AI and enterprise automation across a global med device company.
Reported by Sugandha "Sue" Gupta
Research & Knowledge
Edwards Lifesciences published the 2026 ESC Heart Failure Guidelines detailing updates for transcatheter mitral and tricuspid therapies.
Reported by Anna Kliefoth
Research & Knowledge
Edwards Lifesciences published the 2026 ESC Heart Failure Guidelines detailing updates for transcatheter mitral and tricuspid therapies.
Reported by Matt Booth